Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 11/301% below fair value
$2.05−0.04 (-1.91%)
Close on Nov 12, 2026Market cap $121.74MP/E 29.3Yield –
Foghorn Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Foghorn Therapeutics's total debt was $0 at Dec 31, 2021. For fiscal 2021 it was $0, down 100.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $19.65M | +30.1% |
| FY2019 | Dec 31, 2019 | $15.11M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | $0 | -100.0% |
| Q3 FY2021 | Sep 30, 2021 | $20.00M | +35.2% |
| Q2 FY2021 | Jun 30, 2021 | $20.00M | +32.3% |
| Q1 FY2021 | Mar 31, 2021 | $20.00M | – |
| Q4 FY2020 | Dec 31, 2020 | $19.65M | – |
| Q3 FY2020 | Sep 30, 2020 | $14.79M | – |
| Q4 FY2019 | Dec 31, 2019 | $15.11M | – |
See a number that looks wrong?